Navigation Links
Study Suggests that NGAL Identifies Acute Kidney Injury Early in ICU Patients
Date:10/5/2009

o this study.

"A bedside blood test like this could be tremendously important for critically ill patients. So far therapeutic interventions for patients with AKI have been relatively unsuccessful. This is likely because they are applied late once kidney function is already lost. Knowing which patients are in trouble in advance may allow clinicians to choose therapies that will minimize further harm to the kidneys and may allow for the study of new therapeutic interventions. If further studies confirm our hypothesis, this bedside blood test could become the corner stone of a new therapeutic age," said Dr. Jean-Michel Constantin of the University Hospital of Clermont-Ferrand.

Considering the US, EU and Australia/New Zealand alone, Inverness estimates that in 2008 approximately 2.4 million patients at high risk of AKI were admitted to ICUs. Subject to confirmation through future trials, Inverness also expects the Triage NGAL Test to offer similar diagnostic benefits in hospital emergency rooms.

Inverness supplied the Triage NGAL Tests used in the study at no charge, but did not otherwise fund or sponsor the study.

About Inverness Medical Innovations

By developing new capabilities in near-patient diagnosis, monitoring and health management, Inverness Medical Innovations enables individuals to take charge of improving their health and quality of life. Inverness' global leading products and services, as well as its new product development efforts, focus on infectious disease, cardiology, oncology, drugs of abuse and women's health. Inverness is headquartered in Waltham, Massachusetts.

For more information about Inverness Medical Innovations, please visit our website at http://www.invernessmedical.com.

*The Triage NGAL Test is not currently available for purchase or use in the United States.

Cautionary Note Reg
'/>"/>

SOURCE Inverness Medical Innovations, Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine technology :

1. Bundling Two Generic Low-Cost Heart Drugs Prevents Heart Attack and Stroke in Large, Diverse Population, Observational Clinical Study Shows
2. Telik Announces Publication of Positive Phase 1-2a Results of a Multicenter Study of TELCYTA(R) in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer
3. Prostate Cancer Study Results Published on Patients Treated With CyberKnife Radiosurgery
4. Data on VIVUS Qnexa to be Featured at European Association for the Study of Diabetes Annual Meeting
5. OPAXIO Produces High Rates of Pathologic Complete Remission in Patients with Advanced Esophageal Cancer; Study Paves Way for Potential Registration Trial as Radiation Sensitizer
6. InteKrin Therapeutics Presents Positive Long Term INT131 Preclinical Cardiovascular Safety Data at the 45th Annual European Association for the Study of Diabetes Meeting
7. General Practitioners Write Most Prescriptions for Mental Health Drugs, According to Study from Thomson Reuters and SAMHSA
8. Results from Abbotts PROSPECT Study Provide New Insight into Role of Vulnerable Plaque in Coronary Artery Disease
9. The 60th Annual Meeting of the American Association for the Study of Liver Diseases Boston, MA -- Hynes Convention Center October 31 -- November 3, 2009
10. Mardil, Inc. Announces Positive Preliminary Results of Pilot Study With BACE(TM) Device at Annual TCT Conference
11. AVAC Praises Thai AIDS Vaccine Trial Collaborators and Volunteers for Historic Study

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...ICK, Mass. and LONDON, Nov. 20 /PRNewswire-FirstCa...) today announced that it has received 510(k) clea...FDA) and CE Mark approval to market its WallFlex&#...ent of malignant esophageal strictures (obstructio...r non-resectable esophageal cancer. ,, (Photo:...
(Date:11/20/2009)...YMOUTH MEETING, Pa., Nov. 20 /PRNewswire-USNewswir...icle that questions why currently available medica...re being ignored, ECRI Institute, an independent n...e evidence on Finasteride for Prevention of Prost...r 13, 2009, New York Times article, " Drugs to D...
(Date:11/20/2009)...NCETON, N.J., Nov. 20 So...x or the Company), formerly known as DOR BioPharma...ced today that it has formed a consortium to devel...d other rapidly acting vaccines. Soligenix receive... of Allergy and Infectious Diseases (NIAID), a div...
Breaking Medicine Technology:Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 2Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 3Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 4ECRI Institute Releases Roadmap to the Evidence on Finasteride for Prevention of Prostate Cancer: New Hotline Report to Aid Healthcare Decision Makers and Journalists 2ECRI Institute Releases Roadmap to the Evidence on Finasteride for Prevention of Prostate Cancer: New Hotline Report to Aid Healthcare Decision Makers and Journalists 3Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 2Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 3Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 4Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 5Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 6Crohn 26apos 3Bs 26amp 3B Colitis Foundation Encourages More Virtual Event Participants 3A Thousands Already Helped Foundation Raise Funds for Resear 57790 1Crohn 26apos 3Bs 26amp 3B Colitis Foundation Encourages More Virtual Event Participants 3A Thousands Already Helped Foundation Raise Funds for Resear 57790 2Crohn 26apos 3Bs 26amp 3B Colitis Foundation Encourages More Virtual Event Participants 3A Thousands Already Helped Foundation Raise Funds for Resear 57790 3Crohn 26apos 3Bs 26amp 3B Colitis Foundation Encourages More Virtual Event Participants 3A Thousands Already Helped Foundation Raise Funds for Resear 57790 4T System Updates Free Clinician H1N1 Templates to Latest CDC Guidelines Adds Discharge Instructions 57786 1T System Updates Free Clinician H1N1 Templates to Latest CDC Guidelines Adds Discharge Instructions 57786 2T System Updates Free Clinician H1N1 Templates to Latest CDC Guidelines Adds Discharge Instructions 57786 3Allied Worlds Linda McSmith to Speak at Ohio Association of Ambulatory Surgery Centers Annual Meeting 57782 1Allied Worlds Linda McSmith to Speak at Ohio Association of Ambulatory Surgery Centers Annual Meeting 57782 2Allied Worlds Linda McSmith to Speak at Ohio Association of Ambulatory Surgery Centers Annual Meeting 57782 3
...uly 16 MAP,Pharmaceuticals, Inc. (Nasdaq: MAPP )...2 study evaluating the safety, tolerability and,ph... published in the July,issue of Current Medical Re...ing MAP0004, an orally inhaled and self-administer..., The study results, which were first announced l...
...ble Phase 1 RX-3341 Results -, NEW HAVEN, Conn., ...he "Company"), a development-stage company focused...tics for the treatment of,antibiotic-resistant inf...,2 clinical trial for an intravenous form of antib...ated skin and skin structure infections (cSSSIs).,...
Other Medicine Technology:MAP Pharmaceuticals Announces Publication of MAP0004 Study in Current Medical Research and Opinion 2MAP Pharmaceuticals Announces Publication of MAP0004 Study in Current Medical Research and Opinion 3MAP Pharmaceuticals Announces Publication of MAP0004 Study in Current Medical Research and Opinion 4Rib-X Pharmaceuticals Initiates Phase 2 Trial for RX-3341 In Complicated Skin and Skin Structure Infections 2Rib-X Pharmaceuticals Initiates Phase 2 Trial for RX-3341 In Complicated Skin and Skin Structure Infections 3
(Date:11/20/2009)...EM, N.C., Nov. 20 Samue...o redefine what it means to be "happy" during the ...h a specialty in family counseling and chair of th...ty, Gladding says research shows that it is the pr... even depression during the holidays. ,, That,s...
(Date:11/20/2009)...ed online November 20 in the Journal of the Natio...ars and hopes that often appear in news coverage o... for both the media and journals to help alleviate...d Steven Woloshin, M.D., M.S., of Center for Medic...ealth Policy and Clinical Practice in New Hampshir...
(Date:11/20/2009)...) November 20, 2009Emergency medical service (EMS)...d 350,000 cardiac arrests each year. Only 5 to 10...survive. Better quality cardiopulmonary resuscita...ay be associated with better patient outcome. The...rgest clinical research network to study prehospit...
(Date:11/20/2009)...ne-third buying 90-day supply, study finds , ...a three-month supply of prescription drugs is up t..., according to a new study. , U.S. researchers ... between 2000 and 2005, and found that patients wh...th supply saved an average 29 percent in out-of-po...
(Date:11/20/2009)... Longtime OB/GYN warns against the new breast c...ative Services Task Force. These guidelines may be...an lives. When is it wrong to be safe than sorry? ...ve Services Task Force recommendations, published ...icine, has set off a firestorm in the medical comm...
Breaking Medicine News(10 mins):Health News:Why Holidays Don't Have To Be 'Happy' 2Health News:Promoting healthy skepticism in the news: Helping journalists get it right 2Health News:Effect of real-time CPR feedback reported at resuscitation science symposium 2Health News:Effect of real-time CPR feedback reported at resuscitation science symposium 3Health News:Three-Month Supply Lowers Drug Costs 2Health News:New Breast Cancer Recommendation May Cost Lives While Saving Money 2Health News:New Breast Cancer Recommendation May Cost Lives While Saving Money 3
...al breakthroughs in recent decades have allowed he...nts to live longer. But as their hearts decline in...will experience disability and the need for nursin...ty among people with CHF, as well as the implicati...
...d sense of smell is an early indicator of Parkinso...st can help determine if people with no symptoms e...d be like diagnosing coronary artery disease befor...kinsons Associated Risk Syndrome Study. With Parki...
...nal Health, Inc.,(NYSE: CAH ), a global provider ...nd productivity of health care, plans to release s...ay, Jan. 29, prior to the opening of,trading on th...orresponding slide,presentation, go to the Investo...
...way Clinical Laboratories, (http://www.parkwayclin...ed,clinical reference laboratory located in Bensal...g Mats Sanden, M.D., as medical director, Masood,H...e New Year with a resolve to rapidly grow our vari...
...MedPredict Market Research, a,global provider of p...research, has published "Thought Leader Insight & ...trategic insight for pharma and biotech,companies ...nd cardiovascular disease, however, the,medical ju...
...le in Spanish . , A group of scientists led by ...istry and Molecular Biology at Universitat Autnoma..., an enzyme that is detected in large quantities o...ous. Thus this molecule would serve as a good mark...
Other Medicine News:Health News:Congestive heart failure leads to greater disability, nursing home admissions 2Health News:Risk factors for Parkinson's disease under study 2Health News:Cardinal Health to Announce Second-Quarter Results on January 29 2Health News:Parkway Clinical Laboratories Expands Management Team to Support a National Growth Strategy Centered on Oral Fluid Drug Screening 2Health News:Pipeline for New Obesity Therapies is Focus of New Report 2Health News:UAB research could improve the prognosis and treatment of lung cancer 2
ENDOLOOP Suture Type - 0 PDSII
ENDOLOOP Suture Type - 0 Coated VICRYL
HemoCue 201 DM System, Glucose
Bartels® C. Difficile Toxin A Antigen EIA with Controls
Medicine Products: